Selegiline transdermal system in major depressive disorder
نویسندگان
چکیده
125 ISSN 1758-2008 10.2217/NPY.12.9 © 2012 Future Medicine Ltd Neuropsychiatry (2012) 2(2), 125–134 Summary Selegiline transdermal system (STS) has been approved to treat major depressive disorder in the USA. STS represents a novel generation of monoamine oxidase inhibitors with a superior safety profile to older monoamine oxidase inhibitors, in particular with regard to food interactions. The efficacy and safety of STS has been established in shortand long-term clinical trials. STS expands the range of pharmacological treatment options available to clinicians to treat major depressive disorder, in particular major depressive disorder with atypical features or treatment-resistant depression. This article discusses the mechanism of action of STS, summarizes efficacy and safety data from clinical trials, reviews drug and food interactions with STS and offers suggestions for use of STS in clinical practice.
منابع مشابه
A critical appraisal of the selegiline transdermal system for major depressive disorder.
The selegiline transdermal system (STS) is the first antidepressant transdermal medication approved by the US FDA for the treatment of major depressive disorder. Its unique antidepressant delivery system allows for steady release of selegiline over 24 h with minimal fluctuation in drug serum levels. It is able to deliver high enough central nervous system concentrations required for an antidepr...
متن کاملTransdermal selegiline for the treatment of major depressive disorder
Non-selective inhibition of monoamine oxidase (MAO) enzymes (ie, isoforms A and B) in the brain are associated with clinically significant antidepressant effects. In the US, the selegiline transdermal system (STS; EMSAM) is the first antidepressant transdermal delivery system to receive Food and Drug Administration (FDA) approved labeling for the treatment of major depressive disorder (MDD). Cu...
متن کاملA double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder.
BACKGROUND The monoamine oxidase (MAO) inhibitor selegiline has demonstrated antidepressant efficacy superior to placebo. A selegiline transdermal system (STS) has been developed with unique pharmacokinetic and pharmacodynamic properties that allow inhibition of central nervous system MAO-A and MAO-B enzymes while substantially avoiding inhibition of intestinal and liver MAO-A enzyme. This nove...
متن کاملThe Selegiline Transdermal System (Emsam)
212 P&T® • April 2008 • Vol. 33 No. 4 ABSTRACT Although monoamine oxidase inhib itors (MAOIs) at one time represented the mainstay of therapy for major depressive disorder (MDD), the risk of acute hypertensive reactions following the ingestion of tyramine-rich foods and the consequent need to restrict dietary tyramine represent a barrier to their use. In this article, we present an overview of ...
متن کامل20mg transdermal selegiline daily may be effective and well tolerated in adults with major depression.
Setting 6 sites in the United States; timeframe not specified. Participants Participants were 177 outpatients who met the DSM-IV criteria for major depressive disorder (single episode or recurrent) and had no other primary psychiatric diagnosis. Mean age 42 years (range 20–65); 53% women; 93% white. All participants were free of any psychoactive medications for a minimum of 2 weeks prior to tre...
متن کامل